Cargando…

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy

Detalles Bibliográficos
Autores principales:	Nirmala, N, Wulffraat, N, Brunner, H, Quartier, P, Brik, R, Mccann, L, Ozdogan, H, Rutkowska-Sak, L, Schneider, R, Gerloni, V, Harel, L, Terreri, M, Houghton, K, Joos, R, Kingsbury, D, Lopez-Benitez, J, Radominski, S, Brachat, A, Bek, S, Schumacher, M, Valentin, M, Gram, H, Abrams, K, Martini, A, Ruperto, N, Lovell, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043490/ http://dx.doi.org/10.1186/1546-0096-11-S2-P168

Ejemplares similares

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
por: Kingsbury, D, et al.
Publicado: (2013)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
por: Ruperto, Nicolino, et al.
Publicado: (2018)

PReS-FINAL-2178: Clinical and microarray follow-up of SJIA patients treated with anakinra over the past 10 years in a single institution
por: Punaro, M, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey
por: Gattorno, M, et al.
Publicado: (2008)

PB2156: CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION
por: Kozich, Zhanna, et al.
Publicado: (2023)

PReS-FINAL-2337: The eurofever registry: 3 years of enrollment
por: Federici, S, et al.
Publicado: (2013)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

PReS-FINAL-2194: Evidence-based clinical classification criteria for periodic fevers
por: Federici, S, et al.
Publicado: (2013)

PReS13-SPK-1030: Juvenile dermatomyositis
por: Quartier, P
Publicado: (2013)

Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps
por: Gattorno, M, et al.
Publicado: (2014)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n8ahfpao17gpucod5arq27ndjb